Unmet Need
Up to 20% of women with primary dysmenorrhea do not respond adequately to NSAIDs or oral contraceptives. These patients have limited treatment options, resulting in significant quality-of-life impact and healthcare burden.
Products
Detailed profiles of our drug and device candidates.
DRUG
NAB-DR02
NSAID-Resistant Dysmenorrhea
Our Solution
NAB-DR02 leverages a novel molecular approach delivered via our mucosal adsorption platform to target prostaglandin and non-prostaglandin pain pathways simultaneously, providing relief where traditional NSAIDs fail.
Regulatory Advantage
Pursuing the FDA 505(b)(2) regulatory pathway, which allows us to reference existing safety and efficacy data for the active ingredient while demonstrating the advantages of our novel delivery mechanism — reducing development timelines and costs.